Is Tesamorelin FDA Approved? Approved Uses, Legal Status, and Limits

Yes — tesamorelin is FDA-approved, but only for one narrow use. The agency approved it in 2010 as Egrifta and again in 2019 as Egrifta WR, both indicated for reducing excess visceral abdominal fat in adults living with HIV and lipodystrophy. Tesamorelin is not FDA-approved for general weight loss, bodybuilding, or anti-aging.

What the FDA Actually Approved Tesamorelin For

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It signals the pituitary gland to release more of the body's own growth hormone, which in turn influences how the body stores and breaks down fat.

The approved indication is deliberately narrow. Egrifta and Egrifta WR are approved for HIV-positive adults with lipodystrophy — a condition that causes abnormal fat accumulation, especially deep visceral belly fat — as part of a broader plan that includes diet and exercise.

Two FDA-approved versions exist in the United States:

• Egrifta (tesamorelin for injection): approved in 2010, supplied as a powder that must be reconstituted before a 2 mg subcutaneous dose once daily.
• Egrifta WR (tesamorelin F8): approved in 2019, a ready-to-use formulation given as 1.4 mg subcutaneously once daily with no mixing required.

Product	FDA approval year	Formulation	Typical adult dose
Egrifta	2010	Lyophilized powder, needs reconstitution	2 mg subcutaneously once daily
Egrifta WR	2019	Ready-to-use solution	1.4 mg subcutaneously once daily

What Tesamorelin Is Not Approved For

The FDA has never approved tesamorelin as a general weight-loss drug, and no version of it is indicated for people who do not have HIV-associated lipodystrophy.

• General obesity or cosmetic belly-fat reduction
• Anti-aging or longevity protocols
• Athletic performance or body recomposition
• Use in children, or during pregnancy

Tesamorelin is not FDA-approved for weight loss in the general population. Clinics and websites that suggest otherwise are describing off-label use at best, or selling an unapproved product at worst. Off-label prescribing by a licensed clinician is legal, but it is not the same thing as FDA approval.

Is Tesamorelin Legal in the United States?

Tesamorelin is legal in the US as a prescription medicine. It is not a controlled substance, so it is not scheduled the way anabolic steroids or testosterone are, but it still requires a prescription from a licensed clinician.

That distinction matters when people ask is tesamorelin legal. Holding a legitimately prescribed Egrifta product is legal. Buying "research grade" tesamorelin from an unregulated peptide site, or importing it from overseas without a prescription, is a different situation entirely.

The FDA has issued import alerts covering foreign tesamorelin shipments and warns that unapproved products may not contain the ingredient or the dose listed on the label. Purity, sterility, and potency are not guaranteed for any peptide sold outside the regulated supply chain.

Tesamorelin Peptide FDA Approved: How It Compares With Other Peptides

Tesamorelin is unusual among peptides because it actually has an approved new drug application on file. Most compounds sold in the same online marketplaces do not.

Searches such as is aod-9604 fda approved and is selank fda approved both come back negative — neither has FDA approval for any human use. The same is true for is cjc-1295/ipamorelin fda-approved, a common question among people researching growth hormone stacks; neither peptide in that pair is FDA-approved.

By contrast, is semaglutide fda-approved has a clear yes behind it. Ozempic, Wegovy, and Rybelsus are all FDA-approved products, which is why semaglutide is prescribed in mainstream diabetes and obesity care while tesamorelin stays limited to a specialty HIV indication.

Compound	FDA-approved?	Approved indication
Tesamorelin (Egrifta, Egrifta WR)	Yes	Excess visceral abdominal fat in adults with HIV and lipodystrophy
Semaglutide (Ozempic, Wegovy, Rybelsus)	Yes	Type 2 diabetes, chronic weight management, cardiovascular risk reduction
CJC-1295 / ipamorelin	No	None
AOD-9604	No	None
Selank	No	None

Side Effects, Monitoring, and What to Ask a Doctor

In clinical trials of the approved product, the most frequently reported tesamorelin side effects were injection-site reactions, joint pain, muscle pain, peripheral edema, and tingling or numbness. Tesamorelin also raises IGF-1 levels, which is the main reason it is used cautiously with periodic lab monitoring.

The FDA label advises caution in people with a history of malignancy, and tesamorelin has not been studied for safety in people without HIV. Anyone considering tesamorelin — approved or not — should discuss risks, alternatives, and monitoring with a healthcare professional rather than relying on forum posts or vendor marketing.

In short, tesamorelin is FDA-approved for a real but very specific medical problem, and it is not a general-purpose fat-loss peptide.

COMMON QUESTIONS

Frequently Asked Questions

Is tesamorelin FDA approved for weight loss?

No. Tesamorelin's FDA approval covers only the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss, obesity treatment, or cosmetic fat reduction in people without HIV.

Is tesamorelin legal to buy in the US?

Tesamorelin is legal in the United States as a prescription medicine, and it is not a controlled substance. That means you need a valid prescription from a licensed clinician; buying it from research-chemical websites or importing it without a prescription falls outside the regulated supply chain.

What is the difference between Egrifta and Egrifta WR?

Both products contain tesamorelin and share the same FDA-approved indication. Egrifta, approved in 2010, is a powder that must be reconstituted and is dosed at 2 mg subcutaneously once daily, while Egrifta WR, approved in 2019, is a ready-to-use formulation dosed at 1.4 mg once daily.